If your NSCLC is localized NSCLC ... People without health insurance typically get a lung cancer diagnosis at a later stage of the disease than those who have insurance. A late diagnosis can ...

The only update for patients with stage IV NSCLC without driver alterations is that patients who have HER2-overexpressing (IHC 3+) disease and good performance status can receive trastuzumab ...

The team from Cancer Research UK's Manchester Institute says it has created a new in vitro model of lung squamous cell ...

Treatment resistance and relapse in the most common type of lung cancer can be traced to a protein called agrin, according to ...

Lung cancer is the number one cancer killer in the world. Biomarker testing improves outcomes in stage IV non-small cell lung cancer (NSCLC), however its ...

Lung Cancer Test Predicts Survival in Early Stages Better Than Current Methods ... that patients with metastatic non-squamous non-small cell lung cancer (NSCLC) harboring specific mutations ...

Tagrisso is associated with positive outcomes among patients with unresectable stage 3 EGFR-mutant non-small cell lung cancer ...

This paper explores the potential of mitochondrial-associated programmed-cell-death (mtPCD) patterns as biomarkers for ...

An independent data monitoring board found that BeiGene’s ociperlimab was unlikely to significantly boost overall survival in ...

Eighty-five percent of diagnosed cases of lung cancer are non-small cell lung cancer (NSCLC). In this group, 5% of patients show molecular alterations in the ALK gene involved in cell multiplication.

The FDA is evaluating a new drug application for taletrectinib in patients with ROS1 fusion–positive non–small cell lung ...

EU approves AstraZeneca’s Imfinzi-in combo with chemotherapy to treat patients with resectable non-small cell lung cancer ...